CompletedPhase 2NCT00760149

Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis

Studying Primary pulmonary tuberculosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Radboud University Medical Center
Principal Investigator
Rob Aarnoutse, Pharm-D, PhD
Radboud University Medical Center
Intervention
Rifampicin in higher doses(drug)
Enrollment
150 enrolled
Eligibility
18-65 years · All sexes
Timeline
2010 – 2013

Study locations (1)

Collaborators

European and Developing Countries Clinical Trials Partnership (EDCTP) · Sanofi · Kilimanjaro Christian Medical Centre, Tanzania · Kibong'oto National Tuberculosis Hospital, Sanya Juu, Tanzania · University Centre for Chronic Diseases Dekkerswald, Groesbeek, The Netherlands · National Institute for Public Health and the Environment (RIVM)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00760149 on ClinicalTrials.gov

Other trials for Primary pulmonary tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Primary pulmonary tuberculosis →

← Back to all trials